Sign in Subscribe

real-world

A collection of 53 issues

Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC

Skip to content The CRC Digest ▸ TREATMENT Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC A U.S. healthcare payer analysis evaluated nivolumab plus ipilimumab versus pembrolizumab and chemotherapy as first-line treatment for the 4-5% of metastatic colorectal cancers that are microsatellite instability-high or mismatch repair deficient. (Advances in

Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC

Skip to content The CRC Digest Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy

Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and

AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore

Skip to content The CRC Digest ▪ SCREENING AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore Computer-assisted detection (CADe) during screening colonoscopy improves adenoma detection rates while reducing endoscopists' mental fatigue. (Int J Surg) This content is informational only and does not constitute medical advice. Always consult your oncologist

Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified

Skip to content The CRC Digest ◇ RESEARCH Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified A real-world next-generation sequencing study compared the genomic landscape of early-onset colorectal cancer with average-onset metastatic disease, identifying distinct molecular features in younger patients. (JCO Precision Oncology) This content is informational only and does

Australian audit finds gaps in surveillance colonoscopy guideline adherence

Skip to content The CRC Digest ▪ SCREENING Australian audit finds gaps in surveillance colonoscopy guideline adherence A clinical audit of six Victorian public hospitals assessed concordance of endoscopist-recommended surveillance colonoscopy intervals with 2018 Australian Cancer Council guidelines, identifying opportunities to improve adherence. (Australian Health Review) This content is informational only

Real-World Study Characterizes Colorectal Neoplasia in Adults Under 50

Skip to content The CRC Digest Real-World Study Characterizes Colorectal Neoplasia in Adults Under 50 A single-center study of 152 patients aged 18-49 who underwent colonoscopy between 2018 and 2023 characterized the clinical, anatomical, and histopathological features of colorectal lesions in younger adults. (Journal of Clinical Medicine) This content is

Genetic Risk Stratification Identifies High Adenoma Detection Rates at Colonoscopy

Skip to content The CRC Digest ▪ SCREENING Genetic Risk Stratification Identifies High Adenoma Detection Rates at Colonoscopy A retrospective study of 800 adults from a US health-system biobank who underwent colonoscopy between 2010 and 2025 found that inherited genetic risk may improve yield of adenoma detection and prioritization of colonoscopy

Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery A review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and

Genomic Analysis Reveals Distinct Mutation Patterns in Early-Onset vs. Average-Onset Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Genomic Analysis Reveals Distinct Mutation Patterns in Early-Onset vs. Average-Onset Metastatic CRC A real-world next-generation sequencing study of 1,892 metastatic CRC patients found genomic differences between 376 early-onset cases (diagnosed before age 50) and 1,516 average-onset cases, potentially informing personalized treatment